Fig. 4

Forest plot of proportion of metastatic recurrences in women diagnosed with a HR+ ; b HR−(1–4 years median follow-up) and c HR+ ; d HR− (5–9 years median follow-up) e HR+ ; (f) HR− (10+ years median follow-up)